Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.49 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031259 | 0.88 | AR (0.63) | ARHPGDSS1PR1 | |
| SCHEMBL27027444 | 0.85 | AR (0.44) | ARHPGDSPGRS1PR1 | |
| SCHEMBL29316555 | 0.85 | AR (0.57) | ARPGRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29316564 | 0.84 | AR (0.56) | ARPGRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL27027437 | 0.83 | AR (0.47) | ARHPGDSPGRPTK2 | |
| SCHEMBL29316534 | 0.81 | AR (0.53) | ARPGRTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29316588 | 0.78 | AR (0.66) | AR | |
| SCHEMBL24031263 | 0.77 | AR (0.62) | ARHPGDSPGRS1PR1CYP2C9 | |
| SCHEMBL29316526 | 0.77 | AR (0.49) | ARPGRS1PR1 | |
| SCHEMBL26801770 | 0.76 | AR (0.66) | ARMAPK14CYP2C9MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | ANHORN MEDICINES CO., LTD. (TW) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018149-A1 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | MDM2, PSMG3, ADRM1 | AR 2577/4885HPGDS 2667/4885PGR 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.